Vertex Pharmaceuticals (VRTX) shares tumbled 5.27% in pre-market trading on Tuesday, as investors reacted to the company's mixed third-quarter results and subsequent analyst downgrades. The biotech firm, known for its cystic fibrosis treatments, faced a wave of price target adjustments from major financial institutions.

Several prominent analysts revised their outlook on Vertex following the earnings report. Bernstein cut its target price to $466 from $471, while RBC lowered its target to $415 from $423. Stifel reduced its price target to $445 from $455, maintaining a Hold rating. Barclays analyst Gena Wang, while raising the target slightly to $414 from $408, kept an Equal Weight rating on the stock.

The mixed Q3 results appear to be the primary catalyst for the stock's decline. While Vertex reported third-quarter adjusted profit of $4.80 a share and revenue gains of 11% to $3.08 billion, both topping analysts' forecasts, the market's reaction suggests that some aspects of the results or future guidance fell short of expectations. Investors are likely reassessing Vertex's near-term growth prospects and potential challenges in its drug development pipeline, leading to the significant pre-market sell-off.